Symmetry Partners, LLC Bristol Myers Squibb CO Transaction History

Symmetry Partners, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 11, 2024	SELL	$40.25 - $52.99 $44,556 - $58,659	-1,107 Reduced 5.0%	21,038 $874,000
Q4 2023 Jan 02, 2024	BUY	$48.48 - $57.85 $151,112 - $180,318	3,117 Added 16.38%	22,145 $1.13 Million
Q3 2023 Oct 10, 2023	SELL	$57.89 - $64.73 $238,912 - $267,140	-4,127 Reduced 17.82%	19,028 $1.1 Million
Q1 2023 Apr 03, 2023	BUY	$65.71 - $74.53 $6,899 - $7,825	105 Added 0.46%	23,155 $1.61 Million
Q4 2022 Jan 06, 2023	SELL	$68.48 - $81.09 $575,026 - $680,912	-8,397 Reduced 26.7%	23,050 $1.66 Million
Q3 2022 Oct 03, 2022	SELL	$0.13 - $76.84 $2,960 - $1.75 Million	-22,775 Reduced 42.0%	31,447 $2.24 Million
Q2 2022 Jul 11, 2022	BUY	$72.62 - $79.98 $2.56 Million - $2.82 Million	35,303 Added 186.6%	54,222 $4.18 Million
Q1 2022 Apr 04, 2022	BUY	$61.48 - $73.72 $196,858 - $236,051	3,202 Added 20.37%	18,919 $1.38 Million
Q4 2021 Jan 11, 2022	SELL	$53.63 - $62.52 $80,123 - $93,404	-1,494 Reduced 8.68%	15,717 $980,000
Q2 2021 Jul 07, 2021	SELL	$61.91 - $67.42 $84,878 - $92,432	-1,371 Reduced 7.38%	17,211 $1.15 Million
Q1 2021 May 03, 2021	BUY	$59.34 - $66.74 $27,415 - $30,833	462 Added 2.55%	18,582 $1.17 Million
Q4 2020 Feb 18, 2021	SELL	$57.74 - $65.43 $12,009 - $13,609	-208 Reduced 1.13%	18,120 $1.12 Million
Q3 2020 Nov 03, 2020	SELL	$57.43 - $63.64 $78,162 - $86,614	-1,361 Reduced 6.91%	18,328 $1.11 Million
Q2 2020 Jul 20, 2020	BUY	$54.82 - $64.09 $41,224 - $48,195	752 Added 3.97%	19,689 $1.16 Million
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $878,676 - $1.28 Million	18,937 New	18,937 $1.06 Million

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Symmetry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Symmetry Partners, LLC with notifications on news.